The antigenome: From protein subunit vaccines to antibody treatments of bacterial infections?

Advances in Experimental Medicine and Biology

Volumn 655, Issue , 2009, Pages 90-117

  Giefing, Carmen ^b   Nagy, Eszter ^b   Von Gabain, Alexander ^a  

^a INTERCELL AG   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AFELIMOMAB; ALTASTAPH; ANTHIM; ANTIBIOTIC AGENT; AUROGRAB; BACTERIAL VACCINE; BOTULISM NEUROTOXIN MONOCLONAL ANTIBODY; DIFFGAM; EFUNGUMAB; ENTEROCOCCUS MONOCLONAL ANTIBODY; ETI 211; IC 47; MDX 066; MDX 1388; MONOCLONAL ANTIBODY; PAGIBAXIMAB; PANOBACUMAB; PROTEIN ANTIBODY; PROTEIN SUBUNIT; PSEUDOMONAS AERUGINOSA MONOCLONAL ANTIBODY; RAXIBACUMAB; RECOMBINANT VACCINE; SDRG MONOCLONAL ANTIBODY; STAPHYLOCOCCUS AUREUS MONOCLONAL ANTIBODY; SUBUNIT VACCINE; TEFIBAZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; URTOXAZUMAB; VALORTIM; VERONATE; ANTIGEN;

ANTHRAX; ANTIBODY PRODUCTION; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL GENETICS; BACTERIAL GENOME; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; DRUG COST; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; DRUG USE; ENTEROCOCCAL INFECTION; GENE EXPRESSION PROFILING; GENE SEQUENCE; HEMOLYTIC UREMIC SYNDROME; HOSPITAL INFECTION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PHAGE DISPLAY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEOMICS; PSEUDOMONAS INFECTION; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; HISTORY; IMMUNE SYSTEM; IMMUNOLOGY; METHODOLOGY; REVIEW; VACCINATION;

BACTERIA (MICROORGANISMS);

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CHEMISTRY, PHARMACEUTICAL; GENOME, BACTERIAL; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; VACCINATION; VACCINES, SUBUNIT;

EID: 77955488559     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1132-2_9     Document Type: Article

References (154)

1. Patti JM. Immunotherapeutics for nosocomial infections. Expert Opin Investig Drugs 2004; 13(6):673-9. (Pubitemid 38868057)
2. Tenover F.C. Mechanisms of anti-microbial resistance in bacteria. Am J Med 2006; 119(6 Suppll):S3-10; discussion S62-70.
3. Lipsitch M, Samore MH. Antimicrobial use and anti-microbial resistance: a population perspective. Emerg Infect Dis 2002; 8(4):347-54. (Pubitemid 34415194)
4. Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163(9) :1009-21. (Pubitemid 36548927)
5. Casadevall A. Passive antibody administration (immediat e immunity) as a specific defense against biological weapons. Emerg Infect Dis 2002; 8(8):833-41.
6. Riedel S. Anthrax: a continuing concern in the era of bioterrorism. Proc (Bayl Univ Med Cent) 2005; 18(3):234-43 .
7. Rupprecht CE, Hanlon CA, Hemachudha T. Rabies reexamined. Lancet Infect Dis 2002; 2(6):327-43.
8. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2(9):695-703. (Pubitemid 39200062)
9. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000; 13(4):602-14.
10. Fry BG, K. D. Winkel, J. C. Wickramararna et al. Effectiveness of Snake Antivenom: Species and Regional Venom Variation and Its Clinical Impact. Journal of Toxicology 2003; 22(1) :23-34. (Pubitemid 36368974)
11. Watt CH. Poisonous snakebite treatment in the United States.JAMA 1978; 240(7):654-6.
12. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005; 20(1):17-29.
13. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6(5):343-57.
14. Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment . Future Oncol 2005; 1(2):221-34.
15. Ennis BW; Lippman ME, Dickson RB. The EGF receptor system as a target for anti-rumor therapy. Cancer Invest 1991; 9(5):553-62.
16. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23(9) :1147-57. (Pubitemid 41486396)
17. Anderson EL, Kennedy OJ, Geldmacher KM et al. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996; 128(5 Pt 1):649-53 (Pubitemid 26137723)
18. IMpact-RSV-Study-Group. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Comm ittee of Fetus and Newborn. Pediatrics 1998; 102(5):1211-6.
19. Meinke A, Henics T, Nagy E. Bacterial genomes pave the way to novel vaccines. Curr Opin Microbiol 2004 ; 7(3):314-20. (Pubitemid 38758074)
20. Meinke A, Henics T, Hanner M et al. Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. Vaccine 2005; 23(17 -18):2035-41. (Pubitemid 40341423)
21. Henics T, Winkler B, PfeiferU et al Small-fragmentgenomic libraries for the displayof putative epitopes from clinically significant pathogens. Biorechniques 2003; 35(1):196-202, 204, 206 passim.
22. Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 2002; 99(10):6573-8. (Pubitemid 34526174)
23. Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74(4) :2215-23.
24. Ayliffe GA. The progressive intercontinental spread of methicill in-resistant Staphylococcus aureus, Clio Infect Dis 1997; 24 Suppl 1:S74-9.
25. WeinsteinJW; Roe M, TownsM et al. Resistant enterococci: a prospective study of prevalence, incidence and factors associated with colonization in a university hospital. Infect Control Hosp Epidemiol 1996; 17(1 ):36-41. (Pubitemid 126482560)
26. Zagursky RJ, Olmsted SB, Russell DP et al. Biolnformatics: how it is being used to identify bacterial vaccine candidates. Expert Rev Vaccines 2003; 2(3) :417-36. (Pubitemid 36713368)
27. Adu-Bobie J, Capecchi B. Serruro D et al. Two years into reverse vaccinology. Vaccine 2003; 21 (7-8):605-10 . (Pubitemid 36091968)
28. Lei B, Liu M, Chesney GL et al. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. J Infect Dis 2004; 189(1):79-89. (Pubitemid 38122333)
29. Fleischmann RD, Alland D, Eisen JA et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002; 184(19):5479-90. (Pubitemid 35024395)
30. Cockle PJ, Gordon SV. Lalvani A et al. Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Infect Immun 2002 ; 70(12):6996-7003. (Pubitemid 35387935)
31. Mayers C, Duffield M, Rowe S et al. Analysis of known bacterial protein vaccine antigens reveals biased physical properties and amino acid composition. In: Comparative and Functional Genomics: New York:John Wiley and Sons, Ltd: 2003: 468-478 . (Pubitemid 37321593)
32. De Groot AS. Sbai H, Aubin CS et al. Imrnuno-informatics: Mining genomes for vaccine components . Immunol Cell Biol 2002; 80(3):255-69. (Pubitemid 34639376)
33. Flower DR . Towards in silico prediction of immunogenic epiropes. Trends Immunol 2003; 24(12):667-74. (Pubitemid 37492876)
34. Tettelin H, Masignani V. Cieslewicz MJ et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococ cus agalactiae. Proc Nad Acad Sci USA 2002; 99(19 ):12391-6.
35. Maione D, Margarit I, Rinaudo CD et al. Identification of a universal Group B streptococ cus vaccine by multiple genome screen. Science 2005; 309(5731):148-50. (Pubitemid 40934997)
36. Conway T, Schoolnik GK. Microarray expression profiling: capturing a genome-wide portrait of the rranscriprome. Mol Microbiol 2003; 47(4) :879-89. (Pubitemid 36232788)
37. Merrell DS. Buder SM, Qadri F et al. Host-induced epidemic spread of the cholera bacterium. Nature 2002; 417(6889) :642-5. (Pubitemid 34614821)
38. Voyich JM, Sturdevant DE, Braughton KR et al. Genome-wide protective response used by group A Streptococcus to evade destruction by human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 2003 ; 100(4):1996-2001. (Pubitemid 36254562)
39. Fisher MA. Plikaytis BB, Shinnick TM. Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes.J Bacreriol 2002; 184(14):4025-32. (Pubitemid 34705461)
40. Grifantini R. Bartolini E. Muzzi A et al. Gene expression profile in Neisseria meningitidis and Neisseria lactamica upon host-cell contact: from basic research to vaccine development. Ann NY Acad Sci 2002; 975:202-16. (Pubitemid 36126963)
41. Werner T. Proreomics and regulomics: the yin and yang of functional genomics. Mass Spectrorn Rev 2004; 23(1):25-33.
42. Haas G, Karaali G. Ebermayer K et al. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2002; 2(3):313-24. (Pubitemid 34269985)
43. Cole JN, Ramirez RD, Currie BJ et al. Surface analyses and immune reactivities of major cell wallassociated proteins of group a strepto coccus. Infect Immun 2005; 73(5):3137-46. (Pubitemid 40570384)
44. Rodriguez-Ortega MJ, Norais N, Bensi G et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006; 24(2):191-7. (Pubitemid 43221703)
45. Vytvytska O, Nagy E, Bluggel M et al.. Identification ofvaccine candidate antigens of Staphylococcus aureus by serological proteomeanalysis. Proteomics 2002; 2(5):580-90. (Pubitemid 34507348)
46. Ariel N, Zvi A, Makarova KS et al. Genome-based Biolnformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupledwith proteomic identification of surface-associated antigens. Infect Immun 2003; 71(8):4563-79. (Pubitemid 36919923)
47. Hughes MJ, Moore JC, Lane JD, et al. Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun 2002; 70(3):1254-9. (Pubitemid 34163399)
48. The Word: Pathosphere, New Scientist 2005; 2520:58.
49. Kohler G, Milstein C. Continuous cultures of fused cellssecretingantibody of predefinedspecificity. Nature 1975: 256(5517):495-7.
50. Idee GG. Human anti-mouseantibodies. Arch Pathol Lab Med 2000; 124(6):921-3.
51. Ober RJ, Radu CG, Ghetie V et al. Differences in promiscuity for antibody-FeRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13(12):1551-9. (Pubitemid 33133882)
52. Morrison SL, Johnson MJ, Herzenberg LA et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81(21):6851-5. (Pubitemid 15221019)
53. Bell SJ, Kamm MA. Review article: the clinical role of anti-TNFalphaantibody treatment in Crohns disease. Aliment Pharrnacol Ther 2000: 14(5):501-14. (Pubitemid 30240740)
54. Jones PT, Dear PH, FooteJ et al. Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321(6069):522-5. (Pubitemid 16052256)
55. Tsurushita N, Hinton PR,Kumar S.Design of humanized antibodies: from anti-Tac to Zenapar, Methods 2005; 36(1):69-83. (Pubitemid 40558817)
56. Hwang WY, Almagro JC , Buss TN et al. Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods 2005; 36(1):35-42. (Pubitemid 40558814)
57. Hoogenboom HR, de Bruine AP, Hutton SE et al. Antibody phage display technologyand its applications. Immunotechnology 1998: 4(1):1-20. (Pubitemid 28302180)
58. Hoogenboom HR. Overview of antibody phage-display technologyand its applications. Methods Mol Biol 2002; 178:1-37.
59. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23(9):1105-16. (Pubitemid 41486392)
60. LonbergN. Human antibodiesfrom transgenic animals. Nat Biotechnol 2005; 23(9):1117-25. (Pubitemid 41486393)
61. McCafferty J, Griffiths AD, Winter G et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348(6301):552-4. (Pubitemid 120015109)
62. Smith J, Kontermann RE et al. Antibody phage display technologies with special reference to angiogenesis. FASEB J 2005; 19(3):331-41. (Pubitemid 40316521)
63. Duenas M, Borrebaeck CA. Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication. Biotechnology (NY) 1994: 12(10):999-1002.
64. Griffiths AD, Duncan AR. Strategies for selection of antibodies by phage display. Curr Opin Biotechnol 1998; 9(1):102-8. (Pubitemid 28098323)
65. Spada S., Krebber C, Pluckthun A. Selectively infective phages (SIP). Biol Chem 1997; 378(6):445-56. (Pubitemid 27296317)
66. Winter G, Griffiths AD, Hawkins RE et al. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12:433-55.
67. Marks JD, Hoogenboom HR, Griffiths AD et al. Molecular evolutionof proteinson filamentous phage. Mimicking the strategy of the immune system. J Biol Chem 1992; 267(23):16007-10.
68. Pini A, Viti F, Santucci A et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a markerof angiogenesis eluted from a two-dimensional gel J Biol Chem 1998; 273(34):21769-76. (Pubitemid 28405353)
69. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999: 17(6):568-72. (Pubitemid 29262920)
70. Alt FW;Blackwell TK, Yancopoulos GD. Immunoglobulin genesin transgenic mice. Trendsin Genetics 1985; 1:231-236.
71. Green LL, Hardy MC, Maynard-Currie CE et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7(1):13-21. (Pubitemid 24232374)
72. Lonberg N, Taylor LD, Harding FA et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368(6474):856-9. (Pubitemid 24137750)
73. Tomizuka K, Shinohara T, Yoshida H et al. Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA 2000; 97(2):722-7. (Pubitemid 30070376)
74. Ishida I, Tomizuka K. Yoshida H et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002; 4(1):91-102. (Pubitemid 34437643)
75. Ishida I, Tomizuka K. Yoshida H et al. Trans Chromo Mouse. Biotechnol Genet Eng Rev 2002; 19: 73-82.
76. Harding FA. Lonberg N. Class switching in human immunoglobulin transgenic mice. Ann NY Acad Sci 1995; 764:536-46. (Pubitemid 26136215)
77. YangXD. Corvalan JR. Wang P et al. Fully human anri-interleukin-B monoclonal antibodies: potential therapeutic s for the treatment of inflammatory disease states. J Leukoc Biol 1999; 66(3) :401-10. (Pubitemid 29439246)
78. Foon KA. YangXD. Weiner LM et al. Preclinical and clinical evaluations of ABX-EGF. a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58(3):984-90. (Pubitemid 38221160)
79. Bekker PJ. Holloway DL. Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162. a fully human monoclonal antibod y to RANKL. in postmenopausal women. J Bone Miner Res 2004; 19(7):1059-66. (Pubitemid 41110556)
80. Phan GQ, Yang JC . Sherry RM et al. Cancer regression and autoimmun ity induced by cytotoxic Tlymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100(14):8372-7. (Pubitemid 36842552)
81. Pendley C. Schantz A. Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003; 5(2) :172-9. (Pubitemid 36626459)
82. Lipovsek D. Pluckthun A. In vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 2004; 290(1 -2):51-67. (Pubitemid 38917130)
83. Mattheakis LC. Bhatt RR. Dower WJ. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci USA 1994; 91(19) :9022-6.
84. He M. Taussig MJ. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res 1997; 25(24) :5132-4. (Pubitemid 28022282)
85. Hanes J. Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 1997; 94(10):4937-42. (Pubitemid 27214714)
86. Hanes J,Schaffitzel C. Knappik A et al. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat Biotechnol 2000; 18(12):1287-92.
87. Boder ET. Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15(6):553-7. (Pubitemid 27251573)
88. Harvey BR. Georgiou G. Hayhurst A et al. Anchored periplasmic expression. a versatile technology for the isolation of high-affinity ant ibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci USA 2004; 101(25):9193-8 . (Pubitemid 38812851)
89. Urban JH . Schneider RM. Compte M Alvarez-Vallina L. et al. Selection of functional human ant ibodies from retroviral display libraries. Nucleic Acids Res 2005; 33(4):e35.
90. Reierscn H. Lobersli I. Loset GA et al. Covalent antibody display-an in vitro antibody-DNA library selection system. Nucleic Acids Res 2005; 33(1) :e10.
91. Sepp A. Tawfik DS. Griffiths AD. Microbead display by in vitro compartmentalisation: selection for binding using flow cyrometry, FEBS Lett 2002: 532(3):455-8. (Pubitemid 35441393)
92. Messner E. Koch H. Pluckrhun A. Fast selection of antibodies without antigen purification: adaptation of the protein fragment complementation assay to select antigen-antibody pairs. J Mol Biol 2001; 308(2 ):115-22. (Pubitemid 33043559)
93. Urech DM. Lichtlen P, Barberis A. Cell growth selection system to detect extracellular and transmembrane protein interactions . Biochim Biophys Acta 2003; 1622(2):117-27. (Pubitemid 36860023)
94. Haurum J, Bregenholt S. Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle. IDrugs 2005; 8(5) :404-9. (Pubitemid 40613994)
95. Bird RE. Walker BW: Single chain antibody variable regions. Trends Biotechnol 1991 ; 9(4) :132-7. (Pubitemid 121003095)
96. Kom AA. Malby RL. Caidwell JB et al. Recombinant anti-sialidase single-chainvariable fragment antibody. Char acterization. formation of dimer and higher-molecular-massmultimers and the solution of the crystal structure of the single-chain variable fragmenr/sialidase complex. Eur J Biochern 1994; 221(1):151-7. (Pubitemid 24120557)
97. Holliger P, Prospero T. Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90(14):6444-8. (Pubitemid 23207229)
98. Kom AA. Lah M. Oddie GW et al. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng 1997; 10(4):423-33. (Pubitemid 27252634)
99. Le Gall F, Kipriyanov SM. Moldenhauer G et al. Di-, tri- and tetrarneric single chain Fv antibody fragments against human CD19: effect of valency on cell binding . FEBS Lett 1999; 453(1-2):164-8. (Pubitemid 29335492)
100. Di Paolo C. Willuda J. Kubetzko S et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective anti-tumor activity. Clin Cancer Res 2003; 9(7):2837-48. (Pubitemid 36842130)
101. Korn T. Muller R. Kontermann RE. Bispecific single-chain diabody-mediared killing of endoglin-posirive endothelial cells by cytotoxic T lymphocytes. J Immunother 2004; 27(2):99-106. (Pubitemid 38282729)
102. Hu S. Shively L. Raubirschek A ee al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chainFv-CH3)which exhibits rapid. high-level targeting of xenogrsfis, Cancer Res 1996; 56(13):3055-61.
103. Barnett BB.Smee DF. Malek SM et al. Selective cytotoxicity of ricin A chain irnrnunotoxins towards murine cytomegalovirus-infected cells. Antimicrob Agents Chemother 1996;40(2):470-2. (Pubitemid 26049363)
104. Till MA. Zolla-Pazner S. Gorny MK. et al.. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupledto ricin A chain. Proc Natl Acad Sci USA 1989; 86(6):1987-91. (Pubitemid 19087053)
105. McHugh L. Hu S. Lee BK. et al. Increased affinity and stability of an anti-HIV-l envelope irnmunotoxin bystructure-based mutagenesis. J Biol Chem 2002;277(37):34383-90.
106. Dadachova E. Bryan RA. Frenkel A et al. Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neofonnans infection in murine models. Antimicrob Agents Chemother 2004; 48(3):1004-6. (Pubitemid 38280355)
107. Dadachova E. Burns T. Bryan RA.et al. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother 2004; 48(5):1624-9. (Pubitemid 38544367)
108. Taylor RP. Martin EN. Reinagel ML et al. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model.J Immunol 1997; 159(8):4035-44. (Pubitemid 127469661)
109. Lindorfer MA. Nardin A. Foley PL et al. Targetingof Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. J Immunol 2001; 167(4):2240-9. (Pubitemid 32747536)
110. Behring EA. Kisato, S. Ueberdas zustandekommen der diphterie-immunirar und der tetanus-immunitat bei thieren, Deutch. Med. Woch. 1890;49:1113-1114.
111. Klernperer G. Klemperer, F.Versuche ueber immunisirung und heilung bei der pneumokokkeninfection. Berlin Klin. Wochnschr. 1891; 28:833-835.
112. Casadevall A. Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38(8):1695-702. (Pubitemid 24250712)
113. Flexner S. Jobling.J. W: Serumtreatmentof epidemic cerebro-spinal meningitis. The Journal of Experimental Medicine 1908; 10:141-195.
114. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis 1996; 2(3):200-8. (Pubitemid 126444987)
115. Nadler LM. Stashenko P. Hardy R. et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40(9):3147-54. (Pubitemid 10043516)
116. Wilde MI. Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996; 51(5):865-94.
117. Stiegler G. Katinger H. Therapeutic potential of neutralizing antibodies in the treatment of HIV-l infection. J Antimicrob Chemother 2003; 51(4):757-9. (Pubitemid 36503409)
118. Montefiori DC. Neutralizing antibodies take a swipe at HIV in vivo. Nat Med 2005; 11(6):593-4. (Pubitemid 40868293)
119. Markovic I, Clouse KA. Recentadvances in understanding the molecular mechanisms of HIV-I entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res 2004, 2(3):223-34. (Pubitemid 38854935)
120. Warren HS. Danner RL. Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992, 326(17):1153-7.
121. Abraham E. Why irnmunomodulatory therapies have not workedin sepsis. Intensive Care Med 1999; 25(6):556-66. (Pubitemid 29312588)
122. Reinhart K. Karzai W: Anti-rumornecrosis factor therapy in sepsis: updateon clinical trialsand lessons learned. Crit Care Med 2001, 29(7 Suppl):SI21-5.
123. Manocha S. Feinstein D. Kumar A. Novel therapies for sepsis: antiendotoxin therapies. Expert Opin Investig Drugs 2002; 11(12):1795-812. (Pubitemid 35469923)
124. Burnie JP. Brooks W; Donohoe M et al. Defining antibody targets in Streptococcus oralis infection. Infect Immun 1996, 64(5):1600-8. (Pubitemid 26129822)
125. Burnie JP. Matthews RC. Carter T et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 2000; 68(6):3200-9. (Pubitemid 30340410)
126. Lindahl G. Scalhammar-Carlernalm M. Areschoug T. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev 2005, 18(1):102-27. (Pubitemid 40170663)
127. Burnie JP. Carter TL. Hodgens SJet al. Fungal heat-shock proteins in human disease. FEMS Microbiol Rev 2006; 30(1):53-88.
128. Matthews RC. Burnie JP. Recombinant antibodies: a naturalpartner in combinatorial anti-fungal therapy. Vaccine 2004, 22(7):865-71. (Pubitemid 38177387)
129. Wei W; Lu Q, Chaudry GJ, Leppla SH, Cohen SN. The LDL receptor-related protein LRP6 mediate s internalization and lethality of anthrax toxin. Cell 2006 ; 124(6) :1l41-54.
130. Walsh C. Antibiotics: Actions, Origins, Resistance: ASM Press; 2003.
131. Clarke T. Drug companies snub antibiotics as pipeline threatens to run dry. Nature 2003; 425(6955):225. (Pubitemid 37158368)
132. Biocentury. The Bernstein report. 2006 :p. A2 of 23.
133. Pucci MJ. Use of genomics to select anti-bacterial targets. Biochem Pharmacol 2006 ; 71(7) :1066-72 .
134. Marra A. Can virulence factors be viable anti-bacterial targets? Expert Rev Anti Infect Ther 2004; 2(1) :61-72. (Pubitemid 38735748)
135. Becker D, Selbach M, Rollenhagen C et al. Robust Salmonella metabolism limits possibilities for new anti-microbials. Nature 2006 ; 440(7082):303-7.
136. Schmidr FR. The challenge of multidrug resistance: actual strategies in the development of novel anti bacterials. Appl Microbiol Biotechnol 2004; 63(4) :335-43 .
137. Hughes D. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat Rev Genet 2003; 4(6) :432-41. (Pubitemid 36648143)
138. Holzheimer RG. Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother 2001; 13 Spec No 1(1):159-72. (Pubitemid 34183611)
139. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise . Crit Rev Oncol Hematol 2005 ; 54(1) :1l-29.
140. Mazmanian SK, Skaar EP, Gaspar AH et al. Passage of heme-iron across the envelope of Staphylococcus aureus. Science 2003; 299(5608):906-9. (Pubitemid 36182452)
141. Fleuridor R, Zhong Z, Pirofski L. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J Infect Dis 1998; 178(4) :1213-6. (Pubitemid 28452228)
142. Pier GB, Boyer D, Preston M et al. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol 2004; 173(9): 5671-8 . (Pubitemid 39392155)
143. Barnea Y, Carmeli Y, Gur E et al. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa Ilagellin for treating infections in a murine burn wound model. Plast Reconstr Surg 2006; 117(7) :2284-91. (Pubitemid 44324268)
144. Neville LF, Barnea Y, Harnmer-Munz O et al. Antibodies raised against N'-terminal Pseudomonas aeruginosa Ilagellin prevent mortality in lethal murine models of infection. Int J Mol Med 2005 ; 16(1):165-71.
145. Kling DE, Gravekamp C. Madoff LC et al. Characterization of two distinct opson ic and protective epiropes within the alpha C protein of the group B Streptococcus. Infect Irnmun 1997; 65(4): 1462-7. (Pubitemid 27146639)
146. Bevanger L, Naess al. Mouse-protective antibodies against the Ibc proteins of group B streptococci. Acta Pathol Microbiol Immunol Scand [B] 1985; 93(2) :121-4 .
147. Michel JL, Madoff LC, Kling DE et al. Cloned alpha and beta Cvprotein antigens of group B streptococci elicit protective immunity. Infect Immun 1991; 59(6) :2023-8 .
148. Martin D, Rioux S, Gagnon E et al. Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein. Infect Immun 2002 ; 70(9):4897-901.
149. Park HS, Cleary PP. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005 ; 73(12):7878-86. (Pubitemid 41740271)
150. ISO. Connolly SE, Benach JL. Cutting edge: the spirochetemia of murine relapsing fever is cleared by complement-independent bacter icidal antibodies . J Immunol 2001 ; 167(6) :3029-32. (Pubitemid 32852538)
151. Beedharn RJ, Turnbull PC , Williamson ED. Passive tran sfer of protection against Bacillus anthraci s infection in a murine model. Vaccine 2001 ,19, 31, 4409-16. (Pubitemid 32718664)
152. Little SF, Ivins BE, FellowsPF et al. Passiveprotection by polyclonal ant ibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997; 65(12) :5171-5. (Pubitemid 27513566)
153. Blanpain C, Libert F, Vassart G et al. CCR5 and HIV infection. Receptors Channels 2002; 8(1 ): 19-31.
154. Vernachio JH, Bayer AS, Ames B et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chernother 2006 ; 50(2) :511-8. (Pubitemid 43190960)